Compare Extra Space Storage, Inc. (EXR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Viatris Inc — how do they compare? Extra Space Storage, Inc. trades at $134.38 (market cap $28.12B), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Viatris Inc for 57 Days on average.
| EXR | VTRS | |
|---|---|---|
Market Cap | $28.12B | $20.03B |
Volume | 2,595,579 | 14,109,977 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $18.27 |
52-Week Low | $126.67 | $9.74 |
Typical Hold Time | 108 Days | 57 Days |
Enterprise Value | $41.84B | $32.15B |
Dividend Yield | 4.87% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $133.3, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin improved to 27.79%. Analyst consensus is split evenly between Buy and Hold, with a $158.33 price target suggesting upside. Recent news highlights leadership transition and institutional buying interest.
Outlook is mixed: solid fundamentals and analyst targets support growth, but technical weakness and high valuation ratios pose risks. Investors should weigh steady cash flow and dividend yield against debt levels and market sentiment shifts ahead of earnings.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
